Rectal CBD/hyaluronic acid suppositories reduced symptoms in 81% of men with chronic pelvic pain syndrome over 30 days, with significant improvements in pain and urinary scores.
Urologists treating chronic pelvic pain, men with CP/CPPS exploring treatment options, researchers studying CBD delivery routes for pelvic conditions.
What the researchers found
In this pilot trial, 16 men aged 24–49 with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS) self-administered rectal suppositories containing 100 mg CBD and 6.6 mg hyaluronic acid nightly for 30 days.
The primary outcome — the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) — decreased from a median of 24.5 to 20.0 points (p=0.003), with a median reduction of 7.0 points. Symptom improvement was observed in 81.3% (13 of 16) of participants.
Secondary outcomes also improved: the International Prostate Symptom Score decreased from 14.0 to 12.0 (p=0.033), with voiding symptoms showing the largest improvement. Erectile function scores were also assessed.
The rectal delivery route is notable because it bypasses the first-pass liver metabolism that limits oral CBD bioavailability (documented in RTHC-00246). Direct delivery to the pelvic region may achieve higher local concentrations than oral administration.
Why it matters
CP/CPPS is a common condition with limited treatment options and significant quality-of-life impact. This is one of the first clinical trials of CBD specifically for pelvic pain, and the rectal delivery route addresses CBD's well-known bioavailability problem. While the open-label design means results need confirmation in controlled trials, the 81% response rate is encouraging for a condition where many patients find little relief from standard treatments.
The numbers in context
16 men, ages 24–49. 30-day treatment. NIH-CPSI: 24.5 → 20.0 (p=0.003), median 7.0-point reduction. Improvement in 81.3% (13/16). IPSS: 14.0 → 12.0 (p=0.033). Suppository: 100 mg CBD + 6.6 mg hyaluronic acid, nightly rectal administration.
How the study worked
Single-arm, open-label pilot trial. 16 men (ages 24–49) with CP/CPPS (NIH-CPSI >10, pain subscore ≥4). Self-administered rectal CANNEFF suppositories (100 mg CBD + 6.6 mg hyaluronic acid) nightly for 30 days. Outcomes: NIH-CPSI total score, International Prostate Symptom Score, International Index of Erectile Function. Safety and tolerability assessed.
Who was studied
N=16 men aged 24-49 with chronic pelvic pain syndrome, Czech Republic
What this study cannot tell us
Very small sample (N=16) with no placebo control group — the placebo response in chronic pain conditions is typically 20–40%, so some improvement would be expected without active treatment. Single-arm open-label design cannot establish efficacy. The combined CBD/hyaluronic acid formulation makes it impossible to determine which component is responsible for effects. 30-day treatment period is short for a chronic condition.
How to read the evidence
Small open-label pilot trial without placebo control — provides initial signal of potential benefit but cannot establish efficacy. Designed to justify larger controlled studies.
When this study was published
Published in 2026, representing an early investigation of CBD delivered rectally for pelvic pain conditions.
The bigger picture
This trial takes CBD research in an unusual direction — treating pelvic pain via rectal delivery. It connects to the broader CBD mechanisms review (RTHC-00258) showing anti-inflammatory effects in the gut/pelvic region, and to the bioavailability research (RTHC-00246) that documented challenges with oral CBD. The combination with hyaluronic acid (a tissue-protective agent) represents a multimodal approach that's different from typical cannabinoid studies using single compounds.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Would a placebo-controlled trial confirm these findings? Is the CBD, the hyaluronic acid, or the combination responsible for the improvement? How do rectal CBD tissue concentrations compare to oral administration at the pelvic level?
Read the original research
Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
Biomedical Papers is a peer-reviewed journal focusing on medical research.
Citation
Student, Vladimir; Repa, Vaclav; Vrbkova, Jana; Vacek, Jan. (2026). Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial.. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. https://doi.org/10.5507/bp.2026.002
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- Cannabis and Fibromyalgia: Evidence, Dosing, and What Patients Report
- Cannabis and Carpal Tunnel: Can THC Help Nerve Pain
- Cannabis and Migraines: Prevention, Treatment, and What Studies Show
- Cannabis and Endometriosis: Why Women Are Turning to THC for Pain